.png){kind=icon}
返回
Acotiamide: First Global Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-013-0100-9.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Acotiamide (Acofide (R)), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Unlike other prokinetic drugs that are utilized in the management of functional dyspepsia, acotiamide shows little/no affinity for serotonin or dopamine D-2 receptors. Acotiamide is the world's first approved treatment for functional dyspepsia diagnosed by Rome III criteria, with its first approval occurring in Japan. Phase III trials in this patient population are in preparation in Europe, with phase II trials completed in the USA and Europe. This article summarizes the milestones in the development of acotiamide, leading to its first approval for use in patients with functional dyspepsia.
Keyword:
GUINEA-PIG STOMACH
FUNCTIONAL DYSPEPSIA
GASTROPROKINETIC AGENT
HYDROCHLORIDE Z-338
THERAPEUTIC-EFFICACY
DOUBLE-BLIND
TRIAL
SYMPTOMS
INVOLVEMENT
INHIBITION
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
.png){kind=icon}
分享收藏
查看更多内容